Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novartis

US Appeals Court Revives Regeneron Antitrust Lawsuit Against Novartis

U.S. appeals court revives Regeneron's antitrust lawsuit against Novartis, highlighting alleged anticompetitive behavior.

Top News

What The Future Holds For Google's Money-Losing Moonshots

Google is tweaking its strategy for its 'Other Bets' which could be good news for GOOGLE stock.

Investors Business Daily

How Cytokinetics Overcame Two Setbacks And Doubled Its Stock Price Over A Month

Cytokinetics has shucked off two high-profile setbacks, leading CYTK stock to double as it looks to take on Bristol in heart disease.

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion

Novartis agreed late Monday to buy MorphoSys for about $2.9 billion. The cancer-focused biotech stock catapulted to a nearly three-year high.

Investors Business Daily

Teva, GSK Put Up Bullish Fourth-Quarter Performances. Here's Where Novartis Fell Short.

Teva stock neared a profit-taking zone Wednesday, while GSK stock bounded briefly out of a chase zone on strong fourth-quarter performances for both.

Investors Business Daily

Will These 3 Pharma Stocks Become Gainers in 2024?

The pharmaceutical sector is anticipated to prosper due to the strong demand for drugs and therapies and the adoption of advanced technologies. So, let’s analyze whether pharmaceutical stocks Kamada (KMDA), Neurocrine Biosciences (NBIX), and Novartis (NVS) are well positioned to capitalize on the industry’s growth prospects.

StockNews.com

Cytokinetics Has Clawed Back 105% Over Seven Days. Now It Could Score A Buyout.

Novartis is closing in on a takeover of Cytokinetics, the Wall Street Journal reported Monday, leading CYTK stock to soar in afternoon action.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Hot Biotech Play Breaks Out Into By Range

As biotech stocks boom on a strong 2024 outlook following a rough two years, the XBI ETF launches a fresh breakout.

Investors Business Daily

Alphabet's Isomorphic Labs In Drug Discovery Deals With Eli Lilly, Novartis

Alphabet unit Isomorphic Labs, which uses AI to help discover new drugs, entered collaboration deals with Eli Lilly and Novartis.

Investors Business Daily

Novartis Sweetens Its Deal With Voyager, And VYGR Stock Flashes A Bullish Sign

Novartis expanded its gene therapy collaboration with Voyager on Tuesday, and VYGR stock rocketed above its 200-day line.

Investors Business Daily

Could new malaria drug give babies a better chance of survival?

Trials are under way for a treatment for newborns and infants, who are often wrongly assumed to have immunity through their mothers

The Guardian - UK

Olema Stock Has Soared 551% This Year. Its CEO Thinks It's Still Undervalued.

Olema Oncology is targeting two markets worth $15 billion with the attitude, "we punch above our weight," according to CEO Sean Bohen.

Investors Business Daily

We could see thunderstorm asthma in south-eastern Australia this season – here's how to prepare

Victorians have been warned to prepare for the possibility of thunderstorm asthma again this season.

The Conversation

Novartis Hikes Its Earnings Outlook For The Third Time This Year

Novartis stock inched higher Tuesday after the firm hiked its earnings outlook for the third time this year following its Sandoz spinoff.

Investors Business Daily

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Regeneron Hits A New Record High On The Approval That 'Could Not Come Soon Enough'

Shares of REGN stock jumped Monday after the FDA approved Regeneron Pharmaceuticals' high-dose Eylea following a delay this summer.

The Guardian - UK

Revealed: drug firms funding UK patient groups that lobby for NHS approval of medicines

Observer investigation shows that majority of Nice drug appraisals involve groups financially linked to maker of pharmaceuticals

Investors Business Daily

Dow Jones Futures Rise After Market Rallies On Microsoft AI Push; Netflix, Tesla Earnings On Tap

Microsoft AI pricing fueled the Nasdaq, which is increasingly extended. Netflix and Tesla earnings loom.

Investors Business Daily

Novartis Breaks Out After Putting Up Its Best Profit Growth In Two Years

Novartis stock broke out Tuesday after putting up its best profit growth in two years and raising its outlook for the year.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Drug Maker Novartis Stock Shows Rising Relative Strength

Novartis ADR shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

The Guardian - UK

Panadol maker plans sweeping job cuts a year after being spun off from GSK

Exclusive: Consumer healthcare firm Haleon to cut hundreds of roles in UK and potentially thousands globally

The Guardian - UK

‘It’s naive to think this is in the best interests of the NHS.’ How Big Pharma’s millions are influencing healthcare

Observer investigation shows drug company money flows through the NHS, raising questions about conflict of interest

Investors Business Daily

Meet Chinook Therapeutics, The Company Novartis Is Spending $3.5 Billion To Acquire

Chinook wasn't looking to sell when Novartis approached. But the deal might be the best bet for patients — and KDNY stockholders.

Tribune News Service

Congress ponders whether AI should have the power of the patent

Lawmakers are beginning to consider ways in which artificial intelligence systems are involved in inventive processes like discovery of new drugs, and how the use of such technologies affects what is, and is not, patentable.

Roll Call

Congress ponders whether AI should have the power of the patent - Roll Call

Lawmakers are beginning to consider ways in which artificial intelligence is involved in inventive processes like discovery of new drugs.

Investors Business Daily

Chinook Therapeutics Launches Almost 60% On Novartis' $3.5 Billion Takeover

Novartis said Monday it would pay $3.5 billion to buy kidney disease-focused Chinook Therapeutics, and the biotech stock rocketed almost 60%.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations